Vivos Therapeutics Expands Sleep Apnea Care with Florida Cardiovascular Partnership — Vivos Therapeutics, Inc.

Event summary

Vivos Therapeutics and South Palm Cardiovascular Associates (SPCVA) signed definitive agreements to launch a regional Sleep & Airway Medicine Center (SAMC) in Palm Beach County, Florida.
Vivos will hold a 75% majority stake in the new joint venture, AIM Florida, subject to regulatory approval.
The center is expected to begin treating patients and generating revenue in Q1 2027, with an initial capacity of 250 patients per month.
Vivos projects up to $6 million in annual revenue with contribution margins of 30% or more from the initial team.
SPCVA, a physician-owned cardiology practice, will leverage its 30,000 patient base to expand the referral network for sleep disorder treatments.

The big picture

This partnership aligns with Vivos' strategy to collaborate with large medical specialty groups to expand access to comprehensive obstructive sleep apnea (OSA) care. The move comes as the company seeks to address the significant underserved market of OSA patients, particularly those with cardiovascular conditions. By combining SPCVA's established patient base with Vivos' FDA-cleared diagnostic and treatment methods, the collaboration aims to create a scalable model for growth in the sleep medicine sector.

What we're watching

Revenue Growth: Whether Vivos can sustain the projected $6 million annual revenue and 30% contribution margins from the new SAMC.
Market Expansion: The pace at which Vivos can replicate this model in other U.S. markets through similar partnerships.
Operational Efficiency: How effectively Vivos integrates its technology and operating experience with SPCVA's physician relationships to reduce patient attrition.